These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 22813654)

  • 1. Agonist treatment in opioid use: advances and controversy.
    Viswanath B; Chand P; Benegal V; Murthy P
    Asian J Psychiatr; 2012 Jun; 5(2):125-31. PubMed ID: 22813654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment?
    Mendelson J; Jones RT
    Drug Alcohol Depend; 2003 May; 70(2 Suppl):S29-37. PubMed ID: 12738348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Buprenorphine in the treatment of opiate dependence: its pharmacology and social context of use in the U.S.
    Wesson DR
    J Psychoactive Drugs; 2004 May; Suppl 2():119-28. PubMed ID: 15279124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New drugs for substitution treatment of opioid dependence. Buprenorphine and 1-alpha-acetylmethadol (LAAM) ].
    Petersen H; Skauge L; Svejsø J; Ege PP
    Ugeskr Laeger; 2000 Nov; 162(48):6553-6. PubMed ID: 11187226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Buprenorphine and buprenorphine/naloxone soluble-film for treatment of opioid dependence.
    Soyka M
    Expert Opin Drug Deliv; 2012 Nov; 9(11):1409-17. PubMed ID: 23013384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neonatal Abstinence Syndrome: Presentation and Treatment Considerations.
    Jones HE; Kaltenbach K; Johnson E; Seashore C; Freeman E; Malloy E
    J Addict Med; 2016; 10(4):224-8. PubMed ID: 27244045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buprenorphine and naloxone interactions in opiate-dependent volunteers.
    Mendelson J; Jones RT; Fernandez I; Welm S; Melby AK; Baggott MJ
    Clin Pharmacol Ther; 1996 Jul; 60(1):105-14. PubMed ID: 8689806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In brief: Buprenorphine/naloxone (Zubsolv) for opioid dependence.
    Med Lett Drugs Ther; 2013 Oct; 55(1427):83. PubMed ID: 24129113
    [No Abstract]   [Full Text] [Related]  

  • 9. Buprenorphine for opiate dependence: clinic based therapy in Israel.
    Goren L; Carmel Z; Marchevsky S
    Isr J Psychiatry Relat Sci; 2014; 51(4):281-4. PubMed ID: 25841225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine.
    Strain EC; Walsh SL; Bigelow GE
    Psychopharmacology (Berl); 2002 Jan; 159(2):161-6. PubMed ID: 11862344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anesthesia for patients on buprenorphine.
    Bryson EO; Lipson S; Gevirtz C
    Anesthesiol Clin; 2010 Dec; 28(4):611-7. PubMed ID: 21074741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Buprenorphine: a potential new treatment option for opioid dependence.
    Srivastava A; Kahan M
    CMAJ; 2006 Jun; 174(13):1835. PubMed ID: 16785455
    [No Abstract]   [Full Text] [Related]  

  • 13. Persistence and healthcare utilization associated with the use of buprenorphine/naloxone film and tablet formulation therapy in adults with opioid dependence.
    Clay E; Khemiri A; Zah V; Aballéa S; Ruby J; Asche CV
    J Med Econ; 2014 Sep; 17(9):626-36. PubMed ID: 24841329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Commentary on Rosenthal et al. (2013): Buprenorphine implant-new hopes, old questions.
    Basu D
    Addiction; 2013 Dec; 108(12):2150-1. PubMed ID: 24237901
    [No Abstract]   [Full Text] [Related]  

  • 15. Buprenorphine in combination with naloxone at a ratio of 15:1 does not enhance antinociception from buprenorphine in healthy cats.
    Slingsby LS; Murrell JC; Taylor PM
    Vet J; 2012 Jun; 192(3):523-4. PubMed ID: 22030474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buprenorphine + naloxone: new combination. Opiate dependence: no proof of reduced risk of self-administered injection.
    Prescrire Int; 2007 Dec; 16(92):232-5. PubMed ID: 18087797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence.
    Mammen K; Bell J
    Expert Opin Pharmacother; 2009 Oct; 10(15):2537-44. PubMed ID: 19708849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transdermal buprenorphine patch: Potential for role in management of opioid dependence.
    Dhawan A; Modak T; Sarkar S
    Asian J Psychiatr; 2019 Feb; 40():88-91. PubMed ID: 30772733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OPIOID CRISIS. Prehospital naloxone administration for opioid-related emergencies.
    Drennan IR; Orkin AM
    JEMS; 2016 Mar; 41(3):36-9. PubMed ID: 27120853
    [No Abstract]   [Full Text] [Related]  

  • 20. Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans.
    Eissenberg T; Greenwald MK; Johnson RE; Liebson IA; Bigelow GE; Stitzer ML
    J Pharmacol Exp Ther; 1996 Feb; 276(2):449-59. PubMed ID: 8632309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.